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Background: After addressing fundamental questions in preclinical models in vitro or in small animals in vivo, the
translation into large animal models has become a prerequisite before transferring new findings to human
medicine. Especially in cardiovascular, orthopaedic and reconstructive surgery, the sheep is an important in vivo
model for testing innovative therapies or medical devices prior to clinical application. For a wide variety of sheep
model based research projects, an optimal anticoagulation and antiplatelet therapy is mandatory. However, no
standardised scheme for this model has been developed so far. Thus the efficacy of antiplatelet (acetylsalicylic acid,
clopidogrel, ticagrelor) and anticoagulant (sodium enoxaparin, dabigatran etexilate) strategies was evaluated
through aggregometry, anti-factor Xa activity and plasma thrombin inhibitor levels in sheep of different ages.
Results: Responses to antiplatelet and anticoagulant drugs in different concentrations were studied in the sheep.
First, a baseline for the measurement of platelet aggregation was assessed in 20 sheep. The effectiveness of 225 mg
clopidogrel twice daily (bid) in 2/5 sheep and 150 mg bid in 3/5 lambs could be demonstrated, while clopidogrel
and its metabolite carboxylic acid were detected in every plasma sample. High dose ticagrelor (375 mg bid)
resulted in sufficient inhibition of platelet aggregation in 1/5 sheep, while acetylsalicylic acid did not show any
antiplatelet effect. Therapeutic anti-factor Xa levels were achieved with age-dependent dosages of sodium
enoxaparin (sheep 3 mg/kg bid, lambs 5 mg/kg bid). Administration of dabigatran etexilate resulted in plasma
concentrations similar to human ranges in 2/5 sheep, despite receiving quadruple dosages (600 mg bid).
Conclusion: High dosages of clopidogrel inhibited platelet aggregation merely in a low number of sheep despite
sufficient absorption. Ticagrelor and acetylsalicylic acid cannot be recommended for platelet inhibition in sheep.
Efficient anticoagulation can be ensured using sodium enoxaparin rather than dabigatran etexilate in age-dependent
dosages. The findings of this study significantly contribute to the improvement of a safe and reliable prophylaxis for
thromboembolic events in sheep. Applying these results in future translational experimental studies may help to avoid
early dropouts due to thromboembolic events and associated unnecessary high animal numbers.
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Prior to clinical application, the safety and efficacy of
newly developed therapies or innovative medical devices
have to be ensured. Thus animal models have become an
essential part of researchers' armamentarium in nearly all
fields of experimental research [1]. Especially in the field* Correspondence: justus.beier@uk-erlangen.de
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reproduction in any medium, provided the orof translational and preclinical research, in regard to the
transferability of new therapies to humans, large animals
are indispensable [2]. The sheep is a commonly used
experimental animal model [3], above all due to its human
similarity regarding the vascular and skeletal system. It has
become an irreplaceable animal model, particularly in
research concerning the cardiovascular system, as well as
the investigations of heart assist devices and heart valve
replacement therapy [4]. The sheep is ideally suited to
investigate issues in vitro [5] and in vivo, for example in
orthopaedic traumatology [6] and reconstructive surgery,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with the generation of autonomously vascularised tissue. In
these special experimental setups, optimal anticoagulation
schemes with suitable monitoring are required to ensure
successful procedures, thus avoiding early dropouts be-
cause of vascular obliteration. Studies on anticoagulation
and antiplatelet therapy in sheep are very rare. Most stud-
ies were performed several years to decades ago and report
small experimental groups with conflicting data on possible
strategies, mostly using anticoagulation protocols already
established in humans [9]. To date, the knowledge of the
differences between the sheep and human anticoagulation
system is limited. Only few and sometimes inconsistent data
exist. For example, remarkably different concentrations of
clotting factors in sheep compared to humans are reported
in literature [10]. Due to the different platelet aggregation
characteristics of sheep in comparison to human platelets, a
reliable effect in sheep cannot be guaranteed when applying
human antiplatelet therapy protocols [11,12].
In the human clinical setting, there are a variety of med-
ical options for the prevention of thromboembolic events.
In addition to the newly developed ticagrelor [13], acetyl-
salicylic acid (ASA) and clopidogrel are the most commonly
used platelet aggregation inhibitors [14]. Anticoagulant
protocols based on heparin are applied in a large number
of experimental studies using the sheep in vivo model,
however, due to short effect duration, administration
every 4 hours is necessary [15]. The efficacy of the
inhibition of factor Xa (FXa) by low-molecular-weight
heparin (LMWH) was investigated in a few studies in
adult sheep [16,17], however, never in lambs. Dabigatran
etexilate is a newly developed oral direct thrombin inhibi-
tor [18], for which the feasibility and safety of switching
from enoxaparin is described in literature [19]. However,
no data exist about the usage of this new thrombin inhibi-
tor in sheep.
Since there are no optimal methods for the prevention of
thromboembolic events in sheep, nor standardised meas-
urement methods described so far for the determination of
the antiplatelet effect, the aim of this study was to establish
an optimal thrombosis prophylaxis strategy, as well as a
testing system to ensure the efficacy of an antiplatelet and
anticoagulation therapy in sheep.
Results
Establishment of a method for the assessment of platelet
function in sheep
No standardised measurement method for the assessment
of platelet function in sheep has been described so far,
thus a testing system to evaluate the efficacy of antiplatelet
drugs in sheep was established.
In the impedance aggregometry internal laboratory agon-
ist concentrations for human blood were used to induce
platelet aggregation in sheep blood. Adenosine diphosphate(ADP) (final concentration 6.5 μM) induced platelet aggre-
gation to an extent expected of that for human blood (area
under the curve (AUC) 738 ± 125.87 AU*min). In contrast,
arachidonic acid (AA) (final concentration 0.5 mM) and
thrombin receptor-activating peptide 6 (TRAP-6) (final
concentration 32 μM) could not sufficiently induce platelet
aggregation in sheep blood. Increasing the concentration of
AA up to 6.56 mM and TRAP-6 up to 320 μM did not re-
sult in induction of platelet aggregation. Internal laboratory
human reference ranges were used as target values (AUC
(ADP): 534–1220 AU*min, AUC (AA): 745–1361 AU*min,
AUC (TRAP-6): 941–1563 AU*min). Since not all agonists
could sufficiently induce platelet aggregation, the continued
use of impedance aggregometry was rejected.
In the LTA, final concentrations of 0.19 mg/mL of col-
lagen (col) and 2 × 10-5 M of ADP (concentrations used
for human platelet rich plasma [PRP]) induced adequate
platelet final aggregation (FA) in sheep PRP. The initial
AA concentration of 1.64 mM (concentration used for
human PRP) had to be increased to 10.93 mM to induce
platelet aggregation sufficiently.
Therefore, these concentrations were used for the deter-
mination of reference values evaluating the platelet aggre-
gation of 20 healthy and untreated sheep (col induced FA
(col-FA): 81.6 ± 14.2%, ADP-FA: 87.4 ± 11.6%, AA-FA:
81.9 ± 10.7%). Calculated cut-off values include 53.1% for
col-FA, 64.2% for ADP-FA and 60.6% for AA-FA.
All sheep and lambs survived the experiments unscathed.
No side effects, such as signs of haemorrhage were observed
during the study. Periodically performed counting of plate-
lets resulted in a mean platelet value of 424 ± 128 × 103/μL.
The results of the experimental groups are mentioned
below.
ASA did not inhibit sheep platelet aggregation
The efficacy of ASA in sheep was tested in two different
modes of application over 7 days in the LTA and through
bleeding time (BT) on baseline, days 1, 4 and 7. In
addition, the efficacy of a high concentration of ASA was
evaluated in vitro using LTA.
The application of 500 mg ASA twice a day (bid) per
os (p.o.) (Group 1a) induced no significant differences in
AA and collagen induced platelet final aggregation be-
tween baseline, days 1, 4 and 7 (AA-FA, Figure 1A).
No significant differences were induced with the appli-
cation of 500 mg ASA bid intravenously (i.v.) (Group
1b) between the measurement time points during the 7-
day treatment (AA-FA, Figure 1B). Final aggregation
values in Groups 1a and b did not decline below the
cut-off values at any time point.
BT did not change significantly either after p.o. or
after i.v. administration.
The effect of ASA on sheep platelets was measured
in vitro (Group 1c). The addition of ASA in a final
Figure 1 Acetylsalicylic acid could not inhibit platelet aggregation in vivo and in vitro (Groups 1a–c). A–B: Acetylsalicylic acid (ASA) in a
concentration of 500 mg bid given per os (p.o.) in Group 1a (A) and intravenously (i.v.) in Group 1b (B) had no significant effect on arachidonic acid
induced platelet final aggregation (AA-FA) in the light transmission aggregometry (LTA) between baseline and days 1, 4 and 7, respectively (one-way
repeated measures ANOVA). Values did not decline below the cut-off value at any time point (red line, 60.6%). Platelet aggregation was induced by
10.93 mM arachidonic acid. C: In vitro acetylsalicylic acid failed to inhibit arachidonic acid induced platelet final aggregation of sheep platelet rich
plasma. The platelet aggregation in human platelet rich plasma was inhibited with acetylsalicylic acid in a concentration of 1 mg/mL in LTA. However,
no significant change in sheep platelet final aggregation could be detected after addition of 1 mg/mL or 10 mg/mL acetylsalicylic acid compared to
baseline or control (Friedman Test). Values did not decline below the cut-off value at any time point (red line, 60.6%). Platelet aggregation was induced
by 10.93 mM arachidonic acid. As control, aqua ad injectabilia instead of acetylsalicylic acid solution was used.
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duce any inhibition of sheep platelet final aggregation after
stimulating with AA or collagen compared to the values
of the baseline and control (AA-FA, Figure 1C). Final ag-
gregation values did not decline below the cut-off values
at any ASA concentration. The effect of 1 mg/mL ASA on
human platelets served as positive control (AA-FA: 9%,
col-FA: 100%). After the addition of 10 mg/mL ASA, col-
lagen induced platelet final aggregation still was 78%.
Effect of clopidogrel on sheep and lamb platelet
aggregation
The inhibition of platelet aggregation was evaluated in
sheep in three different dosages over 7 days and in one
dosage in lambs over 28 days using LTA and BT on
baseline, days 1, 4, 7 and 28 (lambs), respectively.
No significant antiplatelet effect could be observed
when clopidogrel was administered to sheep over 7 days
in a concentration of 150 mg bid (Group 2a), 225 mg bid
(Group 2b), 375 mg bid (Group 2c).
The application of 150 mg clopidogrel bid to lambs
over 28 days (Group 2d) induced no significant differ-
ences between baseline and days 1, 4, 7 and 28.Nonetheless, more detailed analysis of the sheep values
revealed a trend towards inhibiting of ADP-FA on day 7
with the increment of the concentration (Figure 2A)
(150 mg bid: 73.8 ± 28.7%, 225 mg bid: 66.8 ± 29.4%,
375 mg bid: 59.6 ± 24.0%). Values below the cut-off value
(64.2%) could be measured on day 7 (ADP-FA: 59.6 ±
24.0%) when administering the highest dosage (375 mg
bid) to sheep and 150 mg bid to lambs on days 7 and 28
(ADP-FA: day 7: 51.8 ± 18.6%, day 28: 57.2 ± 27.8%). In
lambs between days 7 and 28, no significant difference
could be detected.
Considering the sheep and lambs individually in relation
to the cut-off values, intersubject variability can be ob-
served. ADP induced platelet FA decreased below the cut-
off value in 2 out of 5 sheep and in 3 out of 5 lambs. In
Sheep 1, the increase in dosage from 150 mg to 225 mg
and 375 mg bid induced an inhibition of ADP induced
platelet FA below the cut-off value on day 7 (Figure 2B)
(150 mg bid: 76% vs. 225 mg bid: 54% vs. 375 mg bid: 47%).
In Sheep 3, 150 mg bid was sufficient to inhibit ADP in-
duced platelet final aggregation below the cut-off value
from day 4 on. Raising the dosage to 225 mg and 375 mg
bid did not further influence this effect (Figure 2C).
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bid) and 2d (lambs, 150 mg = 5.0–6.0 mg/kg bid), almost
receiving the same dosage per kilogram, no significant dif-
ference could be measured.
BT did not change significantly in each of the concen-
trations tested.
Clopidogrel and clopidogrel carboxylic acid were detected
in every plasma sample. An analysis of the concentrations
of clopidogrel and its main inactive metabolite clopidogrel
carboxylic acid was performed in Groups 2c (sheep,
375 mg = 5.36–6.25 mg/kg bid) and 2d (lambs, 150 mg =
5.0–6.0 mg/kg bid) on baseline, days 1, 4, 7 and 28
(lambs), respectively.
During the 7-day treatment with 375 mg (sheep) and
the 28-day treatment with 150 mg (lambs) clopidogrel
bid, clopidogrel and its metabolite clopidogrel carboxylic
acid were measured in each sample from all sheep and
all lambs (Figure 3).
Calibration range was 0.2–3.6 ng/mL for clopidogrel
and 100–3600 ng/mL for clopidogrel carboxylic acid.
Intraday coefficients of variation ranged from 2.1 to
7.5% for clopidogrel and from 2.3 to 3.7% for clopidogrel
carboxylic acid. The intraday accuracies ranged from
94.6 to 99.1% for clopidogrel and from 100.0 to 107.9%
for clopidogrel carboxylic acid.
There was a highly significant difference in concentration
of clopidogrel carboxylic acid between the measurement
time points in sheep (p ≤ 0.001) and in lambs (p= 0.005). In
sheep, highly significant differences were measured between
every time point (baseline–day 1: p= 0.001, baseline–day 4:
p ≤ 0.001, baseline–day 7: p= 0.001, day 1–4: p= 0.006, day
1–7: p= 0.009), with the exception of days 4 and 7. In lambs,
a significant increase from baseline to day 1 (p= 0.011), day
7 (p = 0.017) and day 28 (p= 0.024) could be detected. NoFigure 2 Clopidogrel inhibited platelet final aggregation adequately
aggregometry (LTA) results of all sheep receiving clopidogrel per os in a do
and 375 mg (green bars, Group 2c) bid (mean ± SD). Platelet aggregation w
significant inhibition of platelet final aggregation could be measured in LTA
(green bars) values declined just below the cut-off value (red line, 64.2%). B
administration of 150 mg clopidogrel bid. Increasing the dosage up to 225
on day 7 declined below the cut-off value (red line, 64.2%). By contrast, in
seen on days 4 and 7 (values below the cut-off value).significant change was seen between all other measurement
time points.
In sheep and lambs, clopidogrel could be detected in each
sample on days 1, 4, 7 and 28, respectively. Values among
sheep and lambs differed greatly. There were no significant
differences between the measurement time points in sheep
and lambs.
There were significant and highly significant differences
concerning the clopidogrel carboxylic acid concentration be-
tween sheep and lambs on days 1, 4 and 7 (day 1: p= 0.031,
day 4: p = 0.011, day 7: p= 0.005). The animal's age had a
highly significant influence on the concentration of the
metabolite (p = 0.004).
No significant differences in clopidogrel plasma con-
centration could be detected between sheep and lambs.
There was no association noticed between clopidogrel
or clopidogrel carboxylic acid concentration and ADP-
FA levels in the individual sheep.
Ticagrelor inhibited platelet aggregation in 1 out of 5
sheep
In Group 3, the antiplatelet agent ticagrelor was adminis-
tered to sheep in four different dosages (Group 3a: 90 mg
bid, Group 3b: 180 mg, Group 3c: 360 mg bid, Group 3d:
540 mg bid) for a time period of 7 days. The efficacy was
tested in LTA and BT on baseline, days 1, 4 and 7.
Mean values after administration of ticagrelor showed
no significant change in platelet final aggregation between
the measurement time points. ADP induced platelet final
aggregation did not decrease below the cut-off values at
any time point. Regarding the values of the individual
sheep in Groups 3c and d (Figure 4), an inhibition of ADP
induced platelet FA below the cut-off value could only be
noticed in Sheep 3 (Group 3c, day 7: 47%; Group 3d, dayin 2 out of 5 sheep (Group 2). A: Calculated light transmission
sage of 150 mg (grey bars, Group 2a), 225 mg (blue bars, Group 2b)
as induced by 2 × 10-5 M adenosine diphosphate (ADP). No
(Friedman Test, one-way repeated measures ANOVA). In Group 2c
–C: Platelet final aggregation of Sheep 1 (B) was not inhibited by
mg (blue bars Group 2b) or 375 mg (green bars, Group 2c) bid, values
Sheep 3 (C) an adequate effect of clopidogrel in every dosage can be
Figure 3 Clopidogrel and clopidogrel metabolite could be detected in every plasma sample in sheep and lambs. Both clopidogrel and
its main inactive metabolite clopidogrel carboxylic acid could be measured in each plasma sample during the 7-day treatment with 375 mg
(5.36–6.25 mg/kg, sheep) and 150 mg (5.0–6.0 mg/kg, lambs) bid. A significant and highly significant increase in the metabolite plasma
concentration between baseline and measurement time points in sheep (blue bars) and in lambs (green bars) could be observed (one-way
repeated measures ANOVA). There were significant and highly significant differences concerning the metabolite concentration between sheep
and lambs (day 1: p = 0.031, day 4: p = 0.011, day 7: p = 0.005, independent t-Test, post hoc Bonferroni Test). The animal's age had a highly
significant influence on the concentration of the metabolite (p = 0.004, two-way repeated measures ANOVA). In sheep and lambs, clopidogrel
could be detected in each sample on days 1, 4, 7 and 28, respectively. However, there was no significant difference between the measurement
time points in sheep (one-way repeated measures ANOVA) and in lambs (Friedman Test, post hoc Wilcoxon Signed Rank Test). Values among
sheep and lambs differed markedly. No significant differences in clopidogrel plasma concentration could be detected between sheep and lambs
(independent t-Test, Mann–Whitney U-Test).
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and measurement time points for BT.
In sheep, human therapeutic anti-FXa levels were
achieved using sodium enoxaparin
The FXa inhibitor sodium enoxaparin was administered
to sheep in two different dosages over 7 days. Its efficacy
was evaluated through anti-FX activity in plasma on
baseline, days 1, 4 and 7.
The administration of a loading dose of 2 mg/kg and
1 mg/kg bid subcutaneous (s.c.) in Group 4a induced
anti-FXa levels below the human prophylactic rangeFigure 4 Light transmission aggregometry after administration of tica
diphosphate in a concentration of 2 × 10-5 M. Regarding the platelet final
dosage of 540 mg bid, an inhibition below the cut-off value (red line, 64.2%
sheep showed no response, with line profiles almost equal and platelet ag
sheep, no significant differences could be noticed between baseline, days(0.40–0.60 IU/mL) (day 1: 0.30 ± 0.05 IU/mL, day 4:
0.20 ± 0.04 IU/mL, day 7: 0.24 ± 0.03 IU/mL). There was
a significant increase in anti-FXa levels, comparing ref-
erence values (0.07 ± 0.05 IU/mL) with day 1 (p = 0.027)
and 7 (p = 0.028). Between baseline and day 4, values
did not differ significantly (Figure 5A, blue bars).
In Group 4b (3 mg/kg bid s.c.) values within the hu-
man therapeutic range (0.60–1.00 IU/mL) were mea-
sured from day 4 on. A highly significant increase was
seen between reference values and day 1 (0.52 ± 0.10
IU/mL, p = 0.007), day 4 (0.77 ± 0.13 IU/mL, p = 0.005)
and day 7 (0.73 ± 0.12 IU/mL, p = 0.003), respectively.grelor (Group 3d). Platelet aggregation was induced by adenosine
aggregation (time point 10 minutes) on day 7 with ticagrelor in a
) could only be noticed in Sheep 3 (final aggregation: 55%). The other
gregation values ranging from 82–98%. Calculating the results of all
1, 4 or 7 (one-way repeated measures ANOVA).
Figure 5 Human therapeutic anti-factor Xa levels in sheep after administration of sodium enoxaparin (Groups 4a–b). A: After the
administration of sodium enoxaparin in a concentration of 1 mg/kg bid (loading dose: 2 mg/kg, Group 4a), human therapeutic anti-factor Xa
levels (0.6–1.0 IU/mL) could not be achieved (blue bars). There was a significant increase in anti-FXa levels comparing reference values with day 1
(p = 0.027) and 7 (p = 0.028). Between baseline and day 4 values did not differ significantly (one-way repeated measures ANOVA, post hoc
Bonferroni Test). The administration of 3 mg/kg sodium enoxaparin (Group 4b) induced values within the human therapeutic range from day 4
on (green bars). A highly significant increase was seen between reference values and day 1 (p = 0.007), day 4 (p = 0.005) and 7 (p = 0.003),
respectively. Between days 4 and 7, values did not differ significantly, indicating the formation of a steady state (one-way repeated measures
ANOVA, post hoc Bonferroni Test). B: Measurement of the anti-factor Xa concentration throughout day 7 of treatment with 3 mg/kg sodium
enoxaparin bid of 2 sheep. Peak plasma levels (0.94 ± 0.01 IU/mL) could be detected 2 hours after the administration of 3 mg/kg. Values rapidly
decreased in the following hours to finally 0.08 ± 0.01 IU/mL 24 hours after injection.
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(Figure 5A, green bars).
Exemplary measurements over 24 hours on day 7 of 2
sheep in Group 4b were performed. The anti-FXa activity
throughout 24 hours revealed peak plasma levels (0.94 ±
0.01 IU/mL) 2 hours after administration of 3 mg/kg,
which rapidly decreased in the next hours to finally 0.08 ±
0.01 IU/mL 24 hours after injection (Figure 5B).
In lambs, human therapeutic anti-FXa levels were
achieved using sodium enoxaparin in a higher dosage
than in sheep
The anti-FXa inhibitor sodium enoxaparin was adminis-
tered to lambs in two different concentrations over 7
days. Its efficacy was evaluated through anti-FX activity
in plasma on baseline, days 1, 4 and 7.
The administration of 3 mg/kg s.c. bid to lambs in
Group 4c could not achieve human therapeutic anti-FXa
activity (0.6–1.0 IU/mL) (day 1: 0.36 ± 0.04 IU/mL, day
4: 0.52 ± 0.09 IU/mL, day 7: 0.48 ± 0.07 IU/mL). No sig-
nificant increase between reference values (0.09 ± 0.02
IU/mL) and days 1, 4 and 7 could be seen (Figure 6).
Comparing these results (Group 4c, lambs 3 mg/kg bid)
with sheep (group 4b, 3 mg/kg bid) receiving the same
concentration of sodium enoxaparin per kilogram, signifi-
cant and highly significant differences in the anti-FXa ac-
tivity were observed (day 1: p = 0.008, day 4: p = 0.008, day
7: p = 0.016), revealing the age to have a significant influ-
ence on the effectiveness of sodium enoxaparin (Figure 6).Raising the dosage to 5 mg/kg s.c. bid in lambs in
Group 4d resulted in anti-FXa activities in the thera-
peutic range from day 4 on (day 1: 0.53 ± 0.11 IU/mL,
day 4: 0.77 ± 0.04 IU/mL, day 7: 0.77 ± 0.10 IU/mL).
There was a highly significant increase between refer-
ence values and days 1 (p = 0.004), 4 (p ≤ 0.001) and 7
(p = 0.001). Between days 4 and 7, values did not differ
significantly (Figure 6).
Therapeutic anti-FXa activity was achieved with the high
dosage in lambs (Group 4d, 5 mg/kg bid) on days 4 and 7
and differs not significantly from that in sheep with the
high dosage (Group 4b, sheep, 3 mg/kg bid) (Figure 6).
Interindividual different and delayed response to
dabigatran etexilate
The direct thrombin inhibitor dabigatran etexilate was
administered to sheep over 7 days in a dosage of 600 mg
bid p.o. Its efficacy was evaluated using the Hemoclot®
test.
In plasma, dabigatran could be determined 4–8 hours
after the first oral application on day 1 (Figure 7A). On
days 4 and 7, maximum dabigatran concentrations were
measured at a time point 6 hours after application (day 7,
Figure 7B). Measurements 24 hours after the last appli-
cation resulted in dabigatran plasma concentration of
0.034 ± 0.027 μg/mL (Figure 7B). There were no sig-
nificant differences when comparing reference values
(0.000 μg/mL) and maximum plasma dabigatran plasma
levels on day 1, day 4 and day 7.
Figure 6 Anti-factor Xa activity of lambs compared to sheep after administration of sodium enoxaparin. Highly significant differences in
the anti-FXa activity were observed administering the same concentration (3 mg/kg bid) of sodium enoxaparin to lambs (Group 4c) and to sheep
(Group 4b) (day 1: p = 0.008 independent t-Test, day 4: p = 0.008 independent t-Test, day 7: p = 0.016 Mann–Whitney U-Test). The treatment of
lambs with 3 mg/kg bid induced no significant increase between reference values and days 1, 4 and 7 (Friedman Test, post hoc Wilcoxon Signed
Rank Test). However, anti-factor Xa concentrations in the human therapeutic range (0.60–1.0 IU/mL) could be reached administering 5 mg/kg
sodium enoxaparin bid to lambs. These data are comparable to Group 4b (sheep, 3 mg/kg bid) without any significant differences (two-way
repeated measures ANOVA). In these two groups, there was a highly significant increase comparing reference values with days 1, 4 and 7,
respectively (p≤ 0.01, one-way repeated measures ANOVA).
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sidering values of the individual sheep on the different
measurement time points. In 2 sheep, plasma concentra-
tions of dabigatran in the range of human values were
detected on day 7 (0.117–0.275 μg/mL, mean 0.175 μg/
mL, 2 hours after administration of 150 mg bid in the
steady state) (Figure 7C).
Discussion
In this study, the efficacy of different antiplatelet drugs and
anticoagulants was evaluated in sheep of different ages in
order to establish a reliable antiplatelet and anticoagulation
therapy for sheep in experimental research. Two different
aggregometry systems were assessed for their ability to
measure platelet function in this species, because to dateFigure 7 Interindividual different and delayed response to dabigatran
etexilate for 7 days. A: Dabigatran could be detected in plasma 4–8 hours
differences between sheep were noticed. B: Both on days 4 and 7, maximu
hours. Twenty-four hours after the last administration, dabigatran plasma c
differences when comparing reference values (0.000 μg/mL) and maximum
measures ANOVA, post hoc Bonferroni Test). C: Interindividual differences c
different measurement time points. Only 2 sheep reached plasma concentno standardised method has been described for the evalu-
ation of platelet aggregation in sheep.
Light transmission aggregometry, but not impedance
aggregometry, serves as a reliable testing system for
evaluation of reference values in healthy and untreated
sheep
The impedance aggregometry provides several advan-
tages compared to LTA, for example, the usage of whole
blood samples preserving the natural environment of the
platelets and the elimination of the time-consuming cen-
trifugation step, thus avoiding the collection of large
blood volumes and the loss of large platelets. The plate-
let volume significantly affects its function [20] with the
mean platelet volume correlating with platelet functionetexilate (Group 5). Sheep were treated with 600 mg dabigatran
after the first oral application of 600 mg dabigatran. Highly individual
m dabigatran concentrations were measured at a time point of 6
oncentration was 0.034 ± 0.027 μg/mL. There were no significant
dabigatran plasma levels on days 1, 4 and 7 (one-way repeated
ould be noted when considering values of the single sheep at the
rations of dabigatran in the range of human values on day 7.
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proved unsuitable for the evaluation of platelet function in
sheep. Our data are concordant with those of the study of
Baumgarten et al., in which neither AA nor TRAP, could
induce measurable platelet aggregation in healthy sheep
[22]. One can assume that there might be other potent
ways for the induction of platelet aggregation in sheep
than stimulation by AA. The lack of response to TRAP
was already regarded by Baumgarten et al. as a reflection
of a species-specific thrombin receptor. Therefore it was
not considered essential to test this system with collagen,
because the same testing system should be used for all
groups in the study. In the LTA, still considered the gold
standard for evaluation of platelet function [23], platelet
aggregation could be induced with all agonists needed for
the study (ADP, collagen and AA). For this reason this sys-
tem was used in every single group.
In every group blood was anticoagulated with citrate
according to the Recommendations of the International
Society on Thrombosis and Haemostasis [24]. However,
it would be possible to anticoagulate the blood with
other agents, such as hirudin or to use washed platelets
to reduce a possible effect of the low calcium concentra-
tion in PRP of citrate anticoagulated blood [25].
The recommended concentrations of ADP and collagen
for human PRP achieved sufficient platelet aggregation in
sheep PRP. AA concentration had to be increased up to
10.93 mmol/L. Sheep possess a higher number of platelets
in contrast to humans and therefore possibly need a higher
concentration of agonists for the induction of platelet ag-
gregation. There seem to be some fundamental differences
in platelet aggregation processes of sheep compared to
humans. Goodman et al. examined platelet-material inter-
actions and showed that platelets of sheep attached to
surfaces much less, never reached fully spread shapes and
displayed a lower overall activity than human platelets [12].
The adhesion of sheep platelets to immobilised fibrinogen
surfaces was, in contrast to other animals, only possible
when stimulated by ADP, although to a lesser extent than
platelets from other animal species [26].
The results of AA induced aggregation in this study are
comparable with previously recorded data showing that
low (2 mmol/L [27]/ 0.5 mmol/L [28]) compared to high
(7.5 mmol/L [11]) concentrations could not reach complete
sheep platelet aggregation in the LTA. In this study, a con-
centration of 10.93 mmol/L AA was identified to be crucial
for an adequate level of aggregation. This difference could
be due to a 3–4 fold interindividual variation, as already
mentioned by Baumgarten et al. [22], especially when work-
ing with small numbers of animals. In addition, the agonists
are obtained by different manufacturers and therefore could
vary in their biological activity [22].
In our laboratory calculated human cut-off values for
the different agonists are established for clinical routineuse, however not for sheep. These reference values should
not be used due to the differences between human and
sheep platelet aggregation and anticoagulation systems.
To increase the reliability of the results of the study, new
cut-offs with blood from healthy untreated sheep of the
same breed were calculated, which revealed quite small
interindividual differences. For data comparison in every
individual sheep, baseline values were measured before
starting the medication.
ASA could not inhibit sheep platelet aggregation both
in vivo and in vitro
There are still many research groups administering acetyl-
salicylic acid (ASA) for the prevention of thromboembolic
events in sheep, without knowing if there is any
antiplatelet effect [29]. ASA induces an inhibition of plate-
let function by irreversible inactivation of the cyclooxygen-
ase activity of prostaglandin H-synthase-1 [30], also
known as cyclooxygenase-1 (COX-1). In our study, inhib-
ition of platelet aggregation through the application of
ASA could be achieved neither in vivo nor in vitro. Data
have been published about the effect of ASA and its
pharmacokinetics in sheep, but never examining the
antiplatelet effect of ASA. In a previous study, the absorp-
tion process of salicylate after oral administration seemed
particularly inefficient in the ruminant animal [31], in this
case possibly due to the coating with gelatin.
The high pH of the rumen favours the existence of the
ionised and non-diffusible form of ASA. In contrast, the
non-ionised and diffusible form dominates in the stom-
ach of monogastrics. Nevertheless, in cattle bioavailabil-
ity of 70% could be achieved with high oral salicylate
concentrations [32].
Therefore, the ineffectiveness of the drug is most likely
not caused by insufficient absorption. When given intra-
venously, a rapid elimination of salicylate from the plasma
of cattle, particularly of goats and sheep, was demon-
strated, probably on the basis of high renal excretion rates
of salicylate [31,32]. ASA induced antiplatelet effects are
attained with only low concentrations and persist over
some days, even when ASA already has been eliminated
from plasma due to the irreversible effect on platelets.
Thus, the rapid disappearance after venous administration
is probably not the explanation for the ineffectiveness.
When examining the effect in the in vitro experiment,
no inhibition of platelet aggregation could be measured.
In the positive control (human PRP), AA induced platelet
aggregation was inhibited with ASA sufficiently, however
not the collagen induced platelet aggregation. Collagen is
probably not as suitable as an agonist, because inhibition
of an aggregation response by aspirin occurs at lower in-
hibition rates of thromboxane A2 (TXA2) synthesis and it
is more variable. AA is described as a more suitable plate-
let agonist than others (for example ADP, collagen), which
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thromboxane production [33]. To prove a sufficient effect
of aspirin on platelet aggregation a nearly complete inhib-
ition of TXA2 synthesis would be a necessary prerequisite
to prevent aggregation induced by a strong agonist such
as thrombin and could be therefore a system to test for as-
pirin resistance. Furthermore one has to keep in mind,
that there are different types of collagen which can lead to
variance in their reactivity. For example collagen type I, II,
III, IV are described to be more reactive than other types
(VI, VII, VIII) [34]. In another study collagen type III was
found to be a more potent inducer of platelet aggregation
than type I and II [35]. Possibly we could achieve different
results using other types of collagens. Moreover collagen
concentration was quite high in our experiments; probably
with lower concentrations inhibition of platelet aggrega-
tion could be detected.
The experimental setup was similar to an early study
of Spanos et al. [36], with the difference of using other
concentrations of aggregation inducing agonists and a
higher concentration of ASA in accordance to the ASA
control of the Multiplate® analyser (1 mg/mL).
Moreover, two previous studies have shown a 37- and
31-fold better ASA induced inhibition of prostaglandin
synthetase from human platelets than from sheep seminal
vesicles, unclear whether depending on the different tissue
origin or not [37,38]. Finally, it can be assumed that sheep
platelet aggregation occurs to a large extent independently
of AA and TXA2, as has already been proposed [36]. The
need of very high concentrations of AA in the LTA to in-
duce aggregation supports this hypothesis.
On the other hand, there could be a TXA2 production
despite ASA administration, either by insufficient inhibition
of COX-1 or COX-1 independent production of TXA2.
Measurement of TXB2 in blood serum could serve for an
indirect assessment of the concentration of TXA2 [39]. It
should be an issue of future studies to determine the under-
lying reasons for the ineffectiveness of ASA in sheep.
Clopidogrel inhibited ADP induced platelet final
aggregation adequately in 2 out of 5 sheep and in 3 out
of 5 lambs, while clopidogrel and clopidogrel carboxylic
acid were detected in every plasma sample
Clopidogrel is an oral ADP receptor antagonist which in-
hibits platelet activation through blockade of the P2Y12
ADP receptor on the platelet surface [40]. An inhibition of
sheep platelet aggregation just below the cut-off value could
be achieved on day 7, when administering the highest dos-
age. The high standard deviations resulted from the high
intersubject variability. In 2 out of 5 sheep and 3 out of 5
lambs an effective inhibition of platelet aggregation could
be shown. No significant changes between days 7 and 28
could be seen, thus indicating the formation of a steady
state after the one-week treatment. In Sheep 3, sufficientinhibition of platelet aggregation could be reached even
with the lowest dosage of clopidogrel, whereas Sheep 1 re-
quired a higher dosage for effective inhibition of platelet ag-
gregation. This observation is possibly due to clopidogrel
resistance: in humans platelet aggregation of low- or non-
responders can be inhibited more effectively when increas-
ing the dosage of clopidogrel [41]. Connell et al. noted only
a modest antiplatelet response to clopidogrel, when treating
2 sheep and goats with 75–150 mg/day [42].
After absorption, the main and inactive metabolite
clopidogrel carboxylic acid is formed by intestinal or
hepatic esterase. Only a very small amount of about
15% is metabolised in the liver through the activity of
different isoenzymes of the P450 system. It is well
known that there are interspecies differences and varia-
tions concerning the drug metabolism mediated by the
cytochrome P450 system [43].
One of the most frequently discussed reasons for
clopidogrel ineffectiveness is the genetic polymorphism
in the cytochrome P450 system (CYP2C19) [44].
CYP2C19 is a highly polymorphic enzyme with more
than 25 different alleles. The most common CYP2C19
loss-of-function allele is the allele *2. While homozy-
gous carriers (*2/*2) have a very low metabolism, in
heterozygous carriers (*1/*2) it is only reduced [45].
However, there are no data concerning the existence of
these gene variants in sheep.
In humans, clopidogrel resistance can occur in the
case of inadequate compliance, poor absorption, non-
optimal dosages, smoking, gene polymorphisms or drug
interactions [46].
However, in sheep, limited efficacy of clopidogrel
could be due to a reduced absorption of clopidogrel, a
degradation or inactivation in the forestomach system,
or an accelerated clearance of the active metabolite, or
the above-mentioned genetic variations concerning the
cytochrome P450 system or the P2Y12 target receptor.
Other explanations for the limited clopidogrel effects
are possibly a higher number of P2Y12 receptors on
sheep platelets, other more important ways of the initi-
ation of platelet aggregation, an accelerated platelet
turnover, or a higher number of platelets in sheep.
In every sample from all sheep, clopidogrel and the
inactive metabolite clopidogrel carboxylic acid were
measured. In 3 out of 10 baseline samples clopidogrel
was measured. Most likely, this was due to laboratory
contamination as definitely none of the animals had re-
ceived any drugs 2 weeks prior to blood collection. The
inactive metabolite clopidogrel carboxylic acid could be
detected in concentrations lower than expected for
such a high dosage. Levels comparable to those in
humans treated with 75 mg/day could not be reached
[47]. Besides a poor absorption, other reasons for the
low metabolite concentrations are probably a lower
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metabolite.
An age-dependency of the concentration of clopidogrel
carboxylic acid in plasma could be revealed. Clopidogrel car-
boxylic acid concentrations were significantly lower in
lambs, although receiving a comparable dosage of clo-
pidogrel, probably due to an accelerated clearance of the
metabolite in young animals. Regarding the individual values
of sheep and lambs, the metabolite concentration seems not
to be linked with the effectiveness of clopidogrel as an
antiplatelet drug. There was no difference in plasma clo-
pidogrel concentration between sheep and lambs. Taken
into account the high individual variability and the high con-
version rate of another clopidogrel metabolite (clopidogrel
glucuronid) into clopidogrel, it is not yet possible to draw a
final conclusion on its exact concentration in sheep blood.
Lambs were treated with clopidogrel for 28 days to investi-
gate if there was an accumulation or an increase of the
clearance of this drug, but neither clopidogrel carboxylic
acid nor clopidogrel concentration changed significantly.
In consideration of the clopidogrel results, one can
presume that an effectiveness of clopidogrel cannot be
ensured on the first day of the treatment when the
steady state has not yet been reached, even not after a
loading dose of 600 mg. Prospective studies with large
groups of animals should be performed to generate suffi-
cient data for the evaluation of the reasons and fre-
quency of non- or low-responders in sheep.
Ticagrelor inhibited ADP induced platelet final
aggregation in only 1 out of 5 sheep
When testing the newly developed direct ADP P2Y12 in-
hibitor ticagrelor in Group 3, 4 out of 5 sheep turned out
to be non-responders. Only in Sheep 3, already showing
good antiplatelet responses to all dosages of clopidogrel,
values below the cut-off value could be detected when ad-
ministering high dosages of ticagrelor. The outcomes of
several human clinical studies comparing clopidogrel and
ticagrelor in favour of the latter and its additional ability
to prevent vasoconstriction through the inhibition of local
P2Y12 receptors in the vascular smooth muscle [13], sug-
gested ticagrelor as a good alternative to clopidogrel. Fur-
thermore, ticagrelor has been described as being superior
to clopidogrel because of its capacity to be effective with-
out the requirement of hepatic conversion. However, this
study revealed only a weak efficacy of ticagrelor in sheep.
These data raise doubts about a deficiency in the cyto-
chrome P450 system in sheep being a factor for the
insufficient effect of clopidogrel. The reasons for the
ineffectiveness of ticagrelor and clopidogrel might be
similar, because of a comparable mode of action and
comparable antiplatelet responses of the sheep. The
poorer efficacy of ticagrelor could be due to the revers-
ible binding and the subsequently faster diffusion ofticagrelor from the P2Y12 receptor. Moreover, there is
a dependency of inhibition of platelet aggregation and
the concentration of the drug in plasma available to
occupy receptors [13]. Taking these findings together,
one reason for the weak efficacy of ticagrelor can be an
accelerated clearance of the drug.
Bleeding time did not serve as a reliable testing system
for the evaluation of platelet aggregation inhibitors in
sheep
BT is an in vivo test for assessing primary haemostasis,
often criticised for its high level of errors due to the wide
normal range in bleeding time and limited reproducibility
[48]. To guarantee a high reliability, a standardised method
was established. The values were considered with respect to
the baseline of every individual sheep because of the high
intervariability. However, no significant prolonging of BT
could be demonstrated. The measurement of antiplatelet
effects via BT seems to be unreliable in sheep, even when
using a standardised technique.
In sheep and lambs, human therapeutic anti-FXa levels
were achieved using sodium enoxaparin in age-
dependent dosages
The administration of 3 mg/kg sodium enoxaparin bid
in sheep resulted in anti-FXa activities in the range of
human therapeutic values, however not on the first day.
It would be conceivable giving a loading dose at the be-
ginning of the treatment. Between days 4 and 7, no sig-
nificant difference of the anti-Xa activity was detectable,
thus indicating the formation of a steady state. Twenty-
four hours after the last injection, only a very low anti-
FXa activity was measured, hence the administration of
3 mg/kg sodium enoxaparin every 12 hours seems to be
necessary. The objective was to achieve human thera-
peutic anti-FXa activities rather than human prophylac-
tic values to ensure the prevention of thromboembolic
events after microvascular surgery.
Only few studies have examined the effect of sodium
enoxaparin in sheep, however, never taking into consider-
ation the animal's age. Other measurement time points,
different anti-FXa assays and weight of the animals compli-
cate direct comparisons [16,17]. Ao et al. investigated the
effect of LMWH on intimal hyperplasia and concluded a
daily dosage of 1 mg/kg to be adequate [17]. Since, in the
present experiment, no haemorrhagic complications were
noticed in any sheep, the higher dosage of 3 mg/kg bid
seems to be decisive for the avoidance of thromboembolic
events in even very small diameter blood vessels in sheep.
When increasing the dosage for lambs from 3 mg/kg
bid up to 5 mg/kg bid, values in the human therapeutic
range could be measured, which were consistent with
those obtained from sheep with a dosage of 3 mg/kg bid.
It became evident that age has a significant influence on
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strated by several studies in humans [49]. Likely explana-
tions for the low effect of sodium enoxaparin in lambs,
other young animals or children are a higher volume of dis-
tribution, an increased total clearance and lower concentra-
tions of antithrombin related to developmental haemostasis
[49]. However, some authors have raised doubts about the
different antithrombin concentrations being a dependent
factor [50,51]. Age-related differences concerning competi-
tive binding to the endothelium, as well as absorption and
clearance of the drug seem to be more important mecha-
nisms [51]. Throughout the present study, human thera-
peutic ranges of anti-FXa activity were considered as target
values. Nevertheless, there are no data available whether
sheep require this activity to reach therapeutic success and
prophylaxis of thromboembolic events. Even in human
medicine, there are no generally accepted regimes available
that could serve as evidence-based guidelines for the pre-
vention of thrombosis in microsurgery [52]. The establish-
ment of a reliable prophylaxis of thromboembolic events in
human and in sheep microsurgery should be an issue of fu-
ture studies.
An experimental group with heparin was not performed
due to the high variability in response in sheep and the
short effect duration leading to a necessary administration
every 4 hours [15,53].
Interindividual different and delayed response to
dabigatran etexilate
The administration of the direct thrombin inhibitor
dabigatran etexilate resulted in dabigatran plasma con-
centrations similar to human ranges only in 2 out of 5
sheep, probably due to a low absorption rate of the
drug. The drug is incorporated in capsules of tartaric
acid to guarantee the formation of a local acid environ-
ment which supports the successful absorption of
dabigatran etexilate [54]. In sheep, the capsule could be
damaged due to the physiological ruminating thus resulting
in a decrement of absorption.
The delayed onset of action (maximum plasma levels 6
hours after administration) compared to humans (0.5–2
hours) and the high inter-individual differences can also
be justified in the special forestomach system and the al-
ways filled rumen of sheep. In humans, when the drug is
taken together with a meal, time for reaching maximum
plasma levels will be prolonged up to 4 hours.
Sheep received quadruple dosages (600 mg) compared
to humans, due to the fact that the administration of 300 mg
bid proved to be inefficient in a pilot study. In recent
studies in swine [55] and rabbit [56] even higher dosages
were used. However, the dosage should not be elevated in
this experiment due to the efficacy in 2 sheep and the in-
creased possibility of bleeding complications. Because of
the unpredictability of an effect of dabigatran etexilatetogether with a delayed onset of action, the administration
of sodium enoxaparin seems to be superior to dabigatran
etexilate as anticoagulant. Nevertheless, there are no data
available whether sheep require the same plasma concen-
trations of dabigatran as humans to achieve an prophylac-
tic effect.
It would be an interesting objective for future stud-
ies to test the efficacy of these established dosages of
antiplatelet and anticoagulant agents in larger groups
of animals in order to obtain more representative data.
The antithrombotic effect of the different drugs
should then be investigated under “real” surgical con-
ditions. Moreover, it could be worth testing to opti-
mise the efficacy when combining an antiplatelet with
an anticoagulant drug.
Conclusion
For the first time, a standardised method for the assessment
of platelet function in sheep as well as baseline values were
established in this study since no standardised tests have
been described so far. The efficacy of different therapeutic
strategies for antiplatelet and anticoagulant management in
different concentrations was compared in sheep and lambs.
In summary, high dosages of clopidogrel or ticagrelor are
useful to inhibit platelet aggregation in some sheep, while
treatment with ASA cannot reach an antiplatelet response.
Examination of the effectiveness of these antiplatelet drugs
should always be performed by LTA due to the presence of
non- or low-responders among sheep and thus the need for
a dose escalation. For a safe anticoagulation regime in sheep
with sodium enoxaparin, it should be administered twice
daily in age-dependent dosages. When using dabigatran
etexilate as anticoagulant, its efficacy should be proven in
each individual sheep before starting an experiment to have
the possibility of a dose escalation. Moreover, its delayed
onset of action has to be carefully considered.
Although only examining a small number of animals,
the data provide significant information about widely used
and novel antiplatelet and anticoagulant agents in sheep.
The results may contribute to overcoming the problems
of high numbers of dropouts due to thromboembolic
events and can support the improvement of a safe and reli-
able thromboembolic prophylaxis in sheep in experimental
research.
The results of this study could make a decisive contri-
bution towards the reduction of unnecessary high animal
numbers in experimental in vivo research.
Methods
Experimental model
The animal care committee of the University of Erlangen-
Nürnberg and the government of Mittelfranken, Germany
approved all experiments (Az. 54–2532.1-44/11, Az.
54.2532.2-2/11). German regulations for the care and use
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animals were housed in the veterinary care facility
under standardised conditions as described previously
[57]. 5 female merino landsheep, aged 1½ years, with a
body weight of 60–70 kg were used. In every group, the
same 5 animals were treated for 7 days with antiplatelet
drugs (ASA, clopidogrel, ticagrelor) or anticoagulants
(sodium enoxaparin, dabigatran etexilate).
The effect of clopidogrel (Group 2d) and sodium
enoxaparin (Group 4c–d) was investigated in the same 5
female lambs, aged 4–5 months, with a body weight of
25–30 kg.
Table 1 summarises the different drugs and dosages.
To establish a reliable test system for the verification
of sheep platelet aggregation and to calculate reference
and cut-off values, blood samples of 20 adult healthy
and untreated female merino landsheep were tested.
In every group baseline values were measured on day
0 before receiving the drugs.
Antiplatelet drugs: ASA, clopidogrel and ticagrelor
Group 1 (n = 5) was treated with 500 mg ASA bid p.o.
(Godamed® 500, Dr. R. Pfleger Chemische Fabrik GmbH,
Bamberg, Germany) (Group 1a) or i.v. (Aspirin® i.v. 500 mg,
Bayer Vital GmbH, Leverkusen, Germany) (Group 1b) via
the Vena auricularis. In Groups 2a–c sheep (n = 5) received
clopidogrel (Plavix®, 75 mg Filmtabletten, Sanofi-Aventis
Deutschland GmbH, Frankfurt am Main, Germany) p.o. in
three different dosages: Group 2a: 150 mg bid, Group 2b:
225 mg bid, Group 2c: 375 mg bid. A loading dose of 300 mg
(Group 2a), 450 mg (Group 2b) or 600 mg (Group 2c) was
administered on the first day.
In Group 2d lambs (n = 5) received clopidogrel in a
dosage of 150 mg bid. The loading dose was 300 mg.
Ticagrelor (Brilique® 90 mg Filmtabletten, AstraZeneca
GmbH, Wedel, Germany) was given to sheep (n = 5) p.o.
in Group 3: Group 3a: 90 mg bid (loading dose 180 mg),
Group 3b: 180 mg bid (loading dose 360 mg), Group 3c:
360 mg (loading dose 540 mg), Group 3d: 540 mg (load-
ing dose 720 mg).
During 7-day treatment, the effect of the antiplatelet
drugs was investigated using LTA and BT 3 hours after
administration on days 1, 4 and 7. In addition, in Group
1b these tests were performed ½ hour after administra-
tion of ASA on day 7. In Group 2d, parameters also
were tested after a treatment period of 28 days. The tab-
lets were pulverised, dissolved in water and administered
p.o. via a syringe.
Sodium enoxaparin and dabigatran etexilate
The LMWH sodium enoxaparin (Clexane® multidose 100
mg/mL, Sanofi-Aventis GmbH Deutschland, Frankfurt,
Germany) was given to sheep (Group 4a: 1 mg/kg s.c. bid,
loading dose 2 mg/kg; Group 4b: 3 mg/kg s.c. bid) andlambs (Group 4c: 3 mg/kg s.c. bid; Group 4d: 5 mg/kg s.c.
bid) (n = 5) for a time period of 7 days.
The anticoagulant effect was determined measuring the
anti-FXa activity on days 1, 4 and 7 4 hours after adminis-
tration. In addition, in Group 4b the anti-FXa activity was
determined after 2, 4, 8, 12 and 24 hours measuring the
values of 2 sheep on day 7.
Group 5 (sheep, n = 5) received dabigatran etexilate
(Pradaxa® 150 mg Hartkapseln, Boehringer Ingelheim
International GmbH, Ingelheim am Rhein, Germany) in a
concentration of 600 mg p.o. bid for 7 days. The capsules
were given to sheep with concentrate, taking care that the
capsules were completely swallowed. Efficacy was evalu-
ated on days 1 (0, 2, 4, 6, 8, 10, 12 hours after administra-
tion), 4 (4, 6, 8, 10 hours after administration) and 7 (0, 2,
4, 6, 8, 10, 12, 24 hours after administration).
Impedance aggregometry
For the assessment of platelet function, through imped-
ance aggregometry, the Multiplate® analyser (Dynabyte
Informationssysteme GmbH, Munich, Germany) was
used. Chosen agonists were ADP (final concentration
6.5 μM), TRAP-6 (final concentration 32 μM and 320 μM)
and AA (final concentration 0.5 mM and 6.5 mM) (all
from Dynabyte Informationssysteme GmbH, Munich,
Germany). Blood samples were collected by jugular
venipuncture with a 14-gauge needle (Introcan Safety®, B.
Braun Melsungen AG, Melsungen, Germany). After
discarding the first 5 mL, the blood was drawn in 2.6 mL
plastic syringes containing hirudin as anticoagulant
(Sarstedt Monovette®, r-Hirudin, Nümbrecht, Germany).
The samples were left for a rest period of 30 minutes at
room temperature. 300 μL of 0.9% sodium chloride,
preheated to a temperature of 37°C, were stirred with the
same volume of blood for 180 seconds at 37°C. The
reaction was started with the addition of 20 μL of
the agonist. Aggregation was continuously recorded
for 6 minutes.
Light transmission aggregometry
For testing the antiplatelet effect of the different drugs,
the LTA (Born's principle [23]) can be used. After
discarding the first 5 mL of the collected blood, it was
placed in 10 mL tubes containing 3.13% sodium citrate
as anticoagulant (Sarstedt Monovette®, 3.13% Citrat,
Nümbrecht, Germany) and left for a rest period of one
hour at room temperature. PRP was prepared by centri-
fuging the blood at 60 × g for 70 minutes, platelet poor
plasma (PPP) by centrifuging at 3 200 × g for 20 minutes
after removal of the PRP. The platelet count was ad-
justed to a range of 150 000–250 000/μL by dilution
with PPP. Baseline values were evaluated by means of
measuring PPP (clear plasma, light transmission set at
100%) and PRP (light transmission set at 0%) in the
Table 1 Experimental groups
Group Age Dose Loading dose Testing system
Sheep Lambs (bid)
n= n=
1
a 5
500 mg p.o.
LTA / BT
(7.14–8.33 mg/kg)
b 5
500 mg i.v.
(7.14–8.33 mg/kg)
c 3 1 mg/mL 10 mg/mL in vitro
2
a 5
150 mg 300 mg
LTA / BT
(2.14–2.5 mg/kg) (4.29–5.0 mg/kg)
b 5
225 mg 450 mg
(3.21–3.75 mg/kg) (6.43–7.5 mg/kg)
c 5
375 mg 600 mg LTA / BT / clopidogrel /
metabolite concentration(5.36–6.25 mg/kg) (8.57–10.0 mg/kg)
d 5
150 mg 300 mg
(5.0–6.0 mg/kg) (10.0–12.0 mg/kg)
3
a 5
90 mg 180 mg
LTA / BT
(1.29–1.5 mg/kg) (2.57–3.0 mg/kg)
b 5
180 mg 360 mg
(2.57–3.0 mg/kg) (5.14–6.0 mg/kg)
c 5
360 mg 540 mg
(5.14–6.0 mg/kg) (7.71–9.0 mg/kg)
d 5
540 mg 720 mg
(7.71–9.0 mg/kg) (10.29–12.0 mg/kg)
4
a 5 1 mg/kg 2 mg/kg
anti-factor Xa activity
b 5 3 mg/kg
c 5 3 mg/kg
d 5 5 mg/kg
5 5
600 mg thrombin inhibitor test
(8.57–10.0 mg/kg)
(BT = bleeding time, LTA = light transmission aggregometry, Group 1: acetylsalicylic acid, Group 2: clopidogrel, Group 3: ticagrelor, Group 4: sodium enoxaparin,
Group 5: dabigatran etexilate).
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Corporation, Pennsylvania, USA). PRP aliquots of 225 μL
were incubated at 37°C for one minute, followed by
the addition of 25 μL of the different agonists. To main-
tain platelets in suspension, a magnetic stirrer was added
to each sample (stirring rate 1 200 rpm). As agonists,
type I calfskin collagen (acid extracted, gallop method)
(final concentration 0.19 mg/mL), ADP (final concentra-
tion 2 × 10-5 M) and AA (final concentration 1.64 mM
and 10.93 mM) were used (all from möLab GmbH,
Langenfeld, Germany). The extent of platelet aggrega-
tion reached after 10 minutes (final aggregation, FA),
was quantified photometrically by the calculation of the
increase in light transmission.
For the determination of the effectiveness of the anti-
platelet drugs, cut-off values were calculated using the
results of blood samples of 20 adult untreated, healthy
female merino landsheep (cut-off [%] =mean (platelet
aggregation) [%] – 2 × SD (platelet aggregation) [%]).Values below the cut-off level indicate the efficacy of the
antiplatelet drugs.
Platelet count
The blood was placed in 2.7 mL tubes containing ethyl-
ene diamine tetraacetic acid (EDTA) as anticoagulant
(Sarstedt Monovette®, EDTA, Nümbrecht, Germany).
Platelets were counted manually in a haemocytometer
chamber on days 0, 1, 4 and 7 in Groups 1–3.
Bleeding time
BT was measured at the ventral non-woollen side of the
tail base with the sheep in a sitting position. A blood
pressure cuff was placed around the base of the tail and
inflated to a pressure of 40 mmHg. An incision 5 mm long
and 1 mm deep was performed (Surgicutt Adult device;
International Technidyne Corporation, Edison, New Jersey,
USA). Blood was blotted from the edges of the wound
every 30 seconds until bleeding stopped without touching
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ing to stop was noted.
FXa chromogenic assay for the evaluation of sodium
enoxaparin efficacy
After discarding the first 5 mL, blood samples were
drawn in 3 mL plastic syringes containing 3.13% sodium
citrate as anticoagulant. Anti-FXa activity was measured
in plasma prepared by centrifugation at 2 200 × g for 10
minutes.
After diluting 50 μL of the plasma (1:2) (STA Diluent
Buffer, Roche Diagnostica Stago S.A.S., Asnières sur
Seine, France) and incubation with 100 μL of chromo-
genic substrate S-2732 for 60 seconds, 125 μL FXa
(lyophilised bovine factor Xa) was added, resulting in
cleavage of p-nitroaniline (pNA) (all from Coamatic®
Heparin, Chromogenix, Milan, Italy). Subsequently, ab-
sorbance change was recorded at 405 nm (STA-R Evolu-
tion® coagulometer; Roche Diagnostics Deutschland
GmbH, Mannheim, Germany).
All standards were prepared from calibration plasma,
all controls from control plasma (calibration plasma
LMW H 1–3/control plasma LMW H Low and High,
Chromogenix, Milan, Italy).
Hemoclot® Thrombin Inhibitors assay for the evaluation
of dabigatran efficacy
Blood collection and plasma preparation were performed
as described above for the anti-FXa assay. Dabigatran ef-
ficacy was evaluated with Hemoclot® Thrombin Inhibi-
tors assay (Hyphen BioMed, Neuville-sur-Oise, France).
100 μL of normal pooled human plasma and 50 μL of the
diluted test plasma (1:8) were incubated in a preheated test
tube at 37°C for one minute. Through addition of 100 μL
of highly purified human α-thrombin (preheated to 37°C),
the clot formation was initiated. Dabigatran concentration
in test plasma was directly proportional to the clotting
time measured by the STA-R Evolution® coagulometer.
All standards were prepared from calibration plasma, all
controls from control plasma (dabigatran calibration plasma
1–3/control plasma, Hyphen BioMed, Neuville-sur-Oise,
France).
Determination of clopidogrel and its metabolite
carboxylic acid in sheep plasma
A validated HPLC-MS/MS method (high-performance
liquid chromatography with tandem mass spectromet-
ric detection) for the determination of clopidogrel and
clopidogrel carboxylic acid, which has already been
published for human plasma [47], was used in this study
with slight modifications. 100 μL sheep plasma were
precipitated by adding 100 μL internal standard solu-
tion (clopidogrel-d3 [10 ng/mL in acetonitrile]) and
110 μL acetonitrile (Acetonitrile hypergrade for LC-MS;Clopidogrel-D3 hydrogen sulfate and clopidogrel car-
boxylic acid, Bertin Pharma, Montigny-le-Bretonneux,
France). After centrifugation, the supernatant was
transferred to an autosampler vial and 10 μL were
injected into the HPLC-MS/MS system (API 4 000
mass spectrometer, Applied Biosystems, Darmstadt,
Germany) equipped with an Agilent 1100 HPLC System
(Agilent Technologies, Waldbronn, Germany). During
all preparation steps, the samples were kept under cooled
conditions. The mass transitions and collision energies
were m/z 321.9 to 212.2 (23 eV) for clopidogrel, m/z 327.1
to 217.3 (23 eV) for clopidogrel-d3 and m/z 308.2 to 113.1
(59 eV) for clopidogrel carboxylic acid.
ASA in vitro
Blood collection from 3 untreated sheep, PRP and PPP
preparation were carried out as described above. ASA so-
lution was prepared freshly through dissolving ASA pow-
der (Aspirin® i.v. 500 mg, Bayer Vital GmbH, Leverkusen,
Germany) in aqua ad injectabilia. PRP with a volume of
200 μL was incubated with 25 μL of ASA solution
with a final concentration of 1 mg/mL or 10 mg/mL
for 3 minutes at 37°C. After addition of 25 μL of the
agonist (AA, final concentration 10.93 mM and colla-
gen, final concentration 0.19 mg/mL), aggregometry
was started. As control, aqua ad injectabilia instead of
ASA solution was used. Reference values were evalu-
ated through adding 25 μL of the agonist to 225 μL
PRP. Human plasma served as positive control.
Statistical analyses
Data are expressed as mean ± standard deviation (SD).
Statistical analysis was performed using the statistical
package, SPSS 18.0 for Windows (SPSS 18.0, SPSS Inc.,
IL, USA). Changes of platelet activity, BT, concentration
of clopidogrel and its metabolite clopidogrel carboxylic
acid, anti-FXa activity and plasma dabigatran concentra-
tion (dependent factor) between the different measure-
ment time points (baseline [day 0], days 1, 4, 7 and 28)
(independent factor, repeated measure factor) within each
group were analysed statistically by one-way analysis of
variance (ANOVA) for repeated measures. Bonferroni cor-
rection for multiple comparisons was used for between
time point comparisons to identify the sources found sig-
nificant by ANOVA. Normal distribution was confirmed
using the Shapiro Wilk Test due to the small group size.
The Greenhouse-Geisser correctional adjustment was ap-
plied due to the small group size. In the case of no normal
distribution, the non-parametric Friedman Test was used
together with the post hoc Wilcoxon Signed Rank Test
with a Bonferroni corrected significance level (α’ = α/m;
α = significance level, m = number of comparisons).
Mean comparisons of anti-FXa activity, clopidogrel
and clopidogrel metabolite concentrations between the
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distribution was confirmed as mentioned above. For
verification of the homogeneity of variances, Levene's
Test of Equality of Error Variances was used. In the case
of no normal distribution, the non-parametric Mann-
Whitney U-Test was applied with a Bonferroni corrected
significance level. In the case of normal distribution,
the influence of the age on the different measurement
results was analysed statistically by two-way analysis
of variance (ANOVA) for repeated measures with age
as between-factor and anti-FXa activity as within-
factor.
The level of statistical significance was set to p ≤ 0.05.
A p-value ≤ 0.01 was considered to be highly significant.
In addition to the statistical analysis, an evaluation with
respect to the established cut-off values was performed in
Groups 1–3. In the case of a platelet aggregation below
these limits, the effectiveness of the administered drug
could be expected.
Abbreviations
AA: Arachidonic acid; ADP: Adenosine diphosphate; ASA: Acetylsalicylic acid;
AUC: Area under the curve; Bid: Bis in die, twice daily; BT: Bleeding time;
Col: Collagen; EDTA: Ethylene diamine tetraacetic acid; FA: Final aggregation;
FXa: Factor Xa; HPLC-MS/MS: High-performance liquid chromatography with
tandem mass spectrometric detection; i.v: intravenous; LTA: Light
transmission aggregometry; p.o: per os, oral; PPP: Platelet poor plasma;
PRP: Platelet rich plasma; s.c: subcutaneous; TRAP-6: Thrombin receptor-
activating peptide 6; TXA2: Thromboxane A2.
Competing interests
All authors confirm that there are no conflicts of interest.
This study was funded by the Baxter Innovations GmbH, Vienna,
Austria; the Xue Hong and Hans Georg Geis foundation, Nürnberg,
Germany; the Staedtler Foundation, Nürnberg, Germany; the research
grants from the University of Erlangen-Nürnberg (ELAN program and
the Forschungsstiftung Medizin).
Authors’ contributions
AW, AMB, JPB, REH conceived and designed the experiments. AW, AMB,
JR, MM performed experiments. AW, AA, AMB, DK, JPB contributed to
data analysis. AW, AA, AMB, JPB, OB, UK contributed to the writing of
the manuscript. All authors discussed and commented on the
manuscript.
Authors’ informations
AW: Born on 14 July 1984 in Hamburg, Germany. 2004–2010 studies in
Veterinary Medicine at the Ludwig-Maximilians University, Munich, Germany.
Since June 2010 Scientific Assistant at the Department of Plastic and Hand
Surgery, University Hospital of Erlangen, Germany (chair: Prof. Dr. R. E. Horch)
with the main focus on tissue engineering of vascularised bone tissue in the
sheep model. 2013 doctoral thesis “Optimization of the generation of axially
vascularised and primary stable bone tissue in the sheep arteriovenous loop
model for the therapy of critical sized bone defects” (Prof. Dr. R. Köstlin,
Center of Clinical Veterinary Medicine, Ludwig-Maximilians University,
Munich, Germany). 2013 postdoctoral fellowship, Friedrich-Alexander
University of Erlangen-Nürnberg, Germany.
AMB: Born on 17 July 1981 in Malsch, Germany. 2001–2008 studies in
Human Medicine at the Albert-Ludwigs University, Freiburg, Germany and
the Ruprecht-Karls-University of Heidelberg. 2005–2006 Scientific Assistant at
the Tumor Biology Center (chair: Prof. Dr. H. G. Augustin), Freiburg, Germany.
2006–2008 Scientific Assistant at the Department of Vascular Oncology and
Metastasis (chair: Prof. Dr. H. G. Augustin), German Cancer Research Center
(DKFZ), Heidelberg. 2010 doctoral thesis "Directly auto-transplanted
mesenchymal stem cells induce bone formation in a ceramic bonesubstitute in an ectopic sheep model". Since 2009 Scientific Assistant in the
tissue engineering laboratory focusing on bone tissue engineering and
angiogenesis research / Fellow at Plastic and Hand Surgery at the
Department of Plastic and Hand Surgery, University Hospital of Erlangen,
Germany (chair: Prof. Dr. R. E. Horch).
JPB: Born on 1 April 1976 in Hamburg, Germany. 1996–2003 studies in
Human Medicine at the Ernst-Moritz-Arndt University, Greifswald, Germany
and the Albert-Ludwigs University, Freiburg, Germany. 1999–2004 doctoral
thesis "Tissue engineering of skeletal muscle tissue" at the Department of
Plastic and Hand Surgery, University Hospital of Freiburg, Germany. 2003–
2005 Resident and Assistant at the Department of Plastic and Hand Surgery,
Freiburg, Germany (chair: Prof. Dr. G-B. Stark). Since January 2005 Assistant
and since 2009 Senior Physician at the Department of Plastic and Hand
Surgery, University Hospital of Erlangen, Germany (chair: Prof. Dr. R. E. Horch).
November 2007 Science Award by the “Deutschsprachige
Arbeitsgemeinschaft für die Mikrochirurgie der peripheren Nerven und
Gefäβe” (DAM). November 2010 habilitation "Tissue engineering of
vascularised skeletal muscle tissue".Acknowledgements
We would like to thank Stefan Fleischer and Marina Milde (Department
of Plastic and Hand Surgery, University Hospital of Erlangen, Friedrich-
Alexander University of Erlangen-Nürnberg, Germany) for their excellent
technical support; Mrs Hahn and colleagues (Department of Transfusion
Medicine and Hemostaseology, University Hospital of Erlangen, Friedrich-
Alexander University of Erlangen-Nürnberg, Germany) for their excellent
technical work and support concerning laboratory anticoagulation and
aggregometry tests. We would like to thank Mr Auge for his technical
work concerning the determination of clopidogrel and clopidogrel
carboxylic acid in plasma (Institute of Experimental and Clinical
Pharmacology and Toxicology, Friedrich-Alexander University of
Erlangen-Nürnberg, Germany).
This work contains parts of Annika Weigand's doctoral thesis.
Author details
1Department of Plastic and Hand Surgery, University Hospital of Erlangen
Friedrich-Alexander University of Erlangen-Nürnberg, Krankenhausstr. 12,
Erlangen D-91054, Germany. 2Department of Transfusion Medicine and
Hemostaseology, University Hospital of Erlangen, Friedrich-Alexander
University of Erlangen-Nürnberg, Erlangen, Germany. 3Institute of
Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander
University of Erlangen-Nürnberg, Erlangen, Germany. 4Department of Hand,
Plastic and Reconstructive Surgery, Burn Center, BG Trauma Center,
Ludwigshafen, Germany.
Received: 23 October 2012 Accepted: 26 September 2013
Published: 3 October 2013References
1. Zanola A, Rossi S, Faggi F, Monti E, Fanzani A: Rhabdomyosarcomas:
an overview on the experimental animal models. J Cell Mol Med 2012,
16(7):1377–1391.
2. Plews JR, Gu M, Longaker MT, Wu JC: Large animal induced pluripotent
stem cells as pre-clinical models for studying human disease. J Cell Mol
Med 2012, 16(6):1196–1202.
3. OBrien EJ, Beveridge JE, Huebner KD, Heard BJ, Tapper JE, Shrive NG, Frank
CB: Osteoarthritis develops in the operated joint of an ovine model
following ACL reconstruction with immediate anatomic reattachment of
the native ACL. J Orthop Res 2012, 31(1):35–43.
4. Locatelli P, Olea FD, De Lorenzi A, Salmo F, Vera Janavel GL, Hnatiuk
AP, Guevara E, Crottogini AJ: Reference values for echocardiographic
parameters and indexes of left ventricular function in healthy,
young adult sheep used in translational research: comparison with
standardized values in humans. Int J Clin Exp Med 2011,
4(4):258–264.
5. Deschepper M, Oudina K, David B, Myrtil V, Collet C, Bensidhoum M,
Logeart-Avramoglou D, Petite H: Survival and function of mesenchymal
stem cells (MSCs) depend on glucose to overcome exposure to
long-term, severe and continuous hypoxia. J Cell Mol Med 2011,
15(7):1505–1514.
Weigand et al. BMC Veterinary Research 2013, 9:192 Page 16 of 17
http://www.biomedcentral.com/1746-6148/9/1926. Hahn JA, Witte TS, Arens D, Pearce A, Pearce S: Double-plating of ovine
critical sized defects of the tibia: a low morbidity model enabling
continuous in vivo monitoring of bone healing. BMC Musculoskel Dis
2011, 12(1):214.
7. Boos AM, Loew JS, Deschler G, Arkudas A, Bleiziffer O, Gulle H, Dragu A,
Kneser U, Horch RE, Beier JP: Directly auto-transplanted mesenchymal
stem cells induce bone formation in a ceramic bone substitute in an
ectopic sheep model. J Cell Mol Med 2011, 15(6):1364–1378.
8. Boos AM, Loew JS, Weigand A, Deschler G, Klumpp D, Arkudas A, Bleiziffer
O, Gulle H, Kneser U, Horch RE, et al: Engineering axially vascularized
bone in the sheep arteriovenous-loop model. J Tissue Eng Regen Med
2013, 7(8):654–664.
9. Macha M, Litwak P, Yamazaki K, Kameneva M, Butler KC, Thomas DC, Taylor
LP, Griffith BP, Borovetz HS: In vivo evaluation of an extracorporeal
pediatric centrifugal blood pump. ASAIO J 1997, 43(4):284–288.
10. Hoehle P: Zur Übertragbarkeit tierexperimenteller endovaskulärer Studien: Unterschiede
der Gerinnungsund Fibrinolyse-Systeme bei häufig verwendeten Tierspezies im Vergleich
zum Menschen. Aachen Germany: RWTH Aachen University; 2000.
11. Pelagalli A, Lombardi P, DAngelo D, Della Morte R, Avallone L, Staiano N:
Species variability in platelet aggregation response to different agonists.
J Comp Pathol 2002, 127(2–3):126–132.
12. Goodman SL: Sheep, pig, and human platelet-material interactions with
model cardiovascular biomaterials. J Biomed Mater Res 1999, 45(3):240–250.
13. Husted S, van Giezen JJ: Ticagrelor: the first reversibly binding oral P2Y12
receptor antagonist. Cardiovasc Ther 2009, 27(4):259–274.
14. Diener HC, Weimar C, Weber R: Antiplatelet therapy in secondary stroke
prevention–state of the art. J Cell Mol Med 2010, 14(11):2552–2560.
15. Park SG, Kim SC, Choi MJ, Lee HS, Min BG, Cheong J, Lee K: Heparin
monitoring in sheep by activated partial thromboplastin time. Artif
Organs 2003, 27(6):576–580.
16. Taylor A, Fletcher JP, Ao PY: Inhibition of fibro-intimal hyperplasia in a
polytetrafluoroethylene vascular graft with standard heparin and low
molecular weight heparin. Aust N Z J Surg 1996, 66(11):764–767.
17. Ao PY, Hawthorne WJ, Coombs R, Fletcher JP: Suppression of intimal
hyperplasia with low molecular weight heparin in a sheep model. Int
Angiol 1999, 18(2):131–139.
18. Van Ryn J, Hauel N, Waldmann L, Wienen W: Dabigatran inhibits both clot-
bound and fluid phase thrombin in vitro: effects compared to heparin
and hirudin. Blood 2007, 110(11):68b–68b.
19. Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M,
Hartter S: Switching from enoxaparin to dabigatran etexilate:
pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin
Pharmacol 2012, 68(5):607–616.
20. Lee JS, Agrawal S, von Turkovich M, Taatjes DJ, Walz DA, Jena BP: Water
channels in platelet volume regulation. J Cell Mol Med 2012, 16(4):945–949.
21. Bath PM, Butterworth RJ: Platelet size: measurement, physiology and
vascular disease. Blood Coagul Fibrinolysis 1996, 7(2):157–161.
22. Baumgarten A, Wilhelmi M, Kalbantner K, Ganter M, Mischke R:
Measurement of platelet aggregation in ovine blood using a new
impedance aggregometer. Vet Clin Pathol 2010, 39(2):149–156.
23. Born GV: Aggregation of blood platelets by adenosine diphosphate and
its reversal. Nature 1962, 194:927–929.
24. Cattaneo M, Cerletti C, Harrison P, Hayward C, Kenny D, Nugent D, Nurden
P, Rao A, Schmaier A, Watson S: Recommendations for the
standardization of light transmission aggregometry: a consensus of the
working party from the platelet physiology subcommittee of SSC/ISTH.
J Thromb Haemost 2013, 11(6):1183–1189.
25. Hu H, Forslund M, Li N: Influence of extracellular calcium on single
platelet activation as measured by whole blood flow cytometry.
Thrombosis Res 2005, 116(3):241–247.
26. Pelagalli A, Belisario MA, Tafuri S, Lombardi P, DAngelo D, Avallone L,
Staiano N: Adhesive properties of platelets from different animal species.
J Comp Pathol 2003, 128(2–3):127–131.
27. Gentry PA, Socha AS, Ross ML: Ovine platelet function and its inhibition
by T-2 toxin. Vet Res Commun 1987, 11(5):457–466.
28. Burke SE, Lefer AM, Nicolaou KC, Smith GM, Smith JB: Responsiveness of
platelets and coronary arteries from different species to synthetic
thromboxane and prostaglandin endoperoxide analogues. Br J Pharmacol
1983, 78(2):287–292.
29. Koch S, Flanagan TC, Sachweh JS, Tanios F, Schnoering H, Deichmann T,
Ella V, Kellomaki M, Gronloh N, Gries T, et al: Fibrin-polylactide-basedtissue-engineered vascular graft in the arterial circulation.
Biomaterials 2010, 31(17):4731–4739.
30. Roth GJ, Stanford N, Majerus PW: Acetylation of prostaglandin synthase
by aspirin. Proc Natl Acad Sci USA 1975, 72(8):3073–3076.
31. Davis LE, Westfall BA: Species differences in biotransformation and
excretion of salicylate. Am J Vet Res 1972, 33(6):1253–1262.
32. Gingerich DA, Baggot JD, Yeary RA: Pharmacokinetics and dosage of
aspirin in cattle. J Am Vet Med Assoc 1975, 167(10):945–948.
33. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet 2006, 367(9510):606–617.
34. Saelman E, Nieuwenhuis HK, Hese KM, de Groot PG, Heijnen H, Sage E,
Williams S, McKeown L, Gralnick H, Sixma J: Platelet adhesion to collagen
types I through VIII under conditions of stasis and flow is mediated by
GPIa/IIa (alpha 2 beta 1-integrin). Blood 1994, 83(5):1244–1250.
35. Balleisen L, Gay S, Marx R, Kühn K: Comparative investigation on the
influence of human bovine collagen types I, II and III on the aggregation
of human platelets. Klin Wochenschr 1975, 53(19):903–905.
36. Spanos HG: Aspirin fails to inhibit platelet aggregation in sheep. Thromb
Res 1993, 72(3):175–182.
37. Majerus PW, Stanford N: Comparative effects of aspirin and diflunisal on
prostaglandin synthetase from human platelets and sheep seminal
vesicles. Br J Clin Pharmacol 1977, 4(Suppl 1):15S–18S.
38. Burch JW, Stanford N, Majerus PW: Inhibition of platelet prostaglandin
synthetase by oral aspirin. J Clin Invest 1978, 61(2):314–319.
39. Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD: Measuring antiplatelet
drug effects in the laboratory. Thromb Res 2007, 120(3):323–336.
40. Gachet C: P2Y(12) receptors in platelets and other hematopoietic and
non-hematopoietic cells. Purinergic Signal 2012, 8(3):609–619.
41. Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, Hwang JY, Park SW:
Randomized comparison of adjunctive cilostazol versus high
maintenance dose clopidogrel in patients with high post-treatment
platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive
Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With
Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009,
53(13):1101–1109.
42. Connell JM, Khalapyan T, Al-Mondhiry HA, Wilson RP, Rosenberg G, Weiss
WJ: Anticoagulation of juvenile sheep and goats with heparin, warfarin,
and clopidogrel. ASAIO J 2007, 53(2):229–237.
43. Zuber R, Anzenbacherova E, Anzenbacher P: Cytochromes P450 and
experimental models of drug metabolism. J Cell Mol Med 2002, 6(2):189–198.
44. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O,
Cayla G, Beygui F, Montalescot G: Cardiovascular risk in clopidogrel-
treated patients according to cytochrome P450 2C19*2 loss-of-function
allele or proton pump inhibitor coadministration: a systematic meta-
analysis. J Am Coll Cardiol 2010, 56(2):134–143.
45. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden
DM, Klein TE, Shuldiner AR: Clinical Pharmacogenetics Implementation
Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype
and clopidogrel therapy. Clin Pharmacol Ther 2011, 90(2):328–332.
46. Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G: Aspirin and
clopidogrel hyporesponsiveness and nonresponsiveness in patients with
coronary artery stenting. Vasc Health Risk Manag 2009, 5:965–972.
47. Silvestro L, Gheorghe M, Iordachescu A, Ciuca V, Tudoroniu A, Rizea Savu S,
Tarcomnicu I: Development and validation of an HPLC-MS/MS method to
quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and
clopidogrel in plasma samples avoiding analyte back-conversion. Anal
Bioanal Chem 2011, 401(3):1023–1034.
48. Segura D, Monreal L: Poor reproducibility of template bleeding time in
horses. J Vet Intern Med 2008, 22(1):238–241.
49. Bauman ME, Belletrutti MJ, Bajzar L, Black KL, Kuhle S, Bauman ML, Patricia
Massicotte M: Evaluation of enoxaparin dosing requirements in infants
and children. Better dosing to achieve therapeutic levels. Thromb
Haemost 2009, 101(1):86–92.
50. Andrew M, Ofosu F, Brooker L, Buchanan MR: The comparison of the
pharmacokinetics of a low molecular weight heparin in the newborn
and adult pig. Thromb Res 1989, 56(4):529–539.
51. Ignjatovic V, Summerhayes R, Newall F, Monagle P: The in vitro response
to low-molecular-weight heparin is not age-dependent in children.
Thromb Haemost 2010, 103(4):855–856.
52. Schmitz M, Riss R, Kneser U, Jokuszies A, Harder Y, Beier JP, Schafer DJ, Vogt
PM, Fansa H, Andree C, et al: [Perioperative coagulation management in
microsurgery: report of the consensus workshops in the course of the
Weigand et al. BMC Veterinary Research 2013, 9:192 Page 17 of 17
http://www.biomedcentral.com/1746-6148/9/19231st and 32nd Annual Meeting of the German-language Working Group
for microsurgery of the peripheral nerves and vessels (DAM) November
2009 in Erlangen and November 2010 in Basel]. Handchir Mikrochir Plast
Chir 2011, 43(6):376–383.
53. Boni L, Sasaki T, Ferrier WT, Yeung JT, Reichenbach SH, Riemer RK, Reinhartz
O: Challenges in longer-term mechanical support of fontan circulation in
sheep. ASAIO J 2012, 58(1):60–64.
54. Hankey GJ, Eikelboom JW: Dabigatran etexilate: a new oral thrombin
inhibitor. Circulation 2011, 123(13):1436–1450.
55. Schomburg JL, Medina EM, Lahti MT, Bianco RW: Dabigatran versus
warfarin after mechanical mitral valve replacement in the swine model.
J Invest Surg 2012, 25(3):150–155.
56. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N: Antithrombotic and
anticoagulant effects of the direct thrombin inhibitor dabigatran, and its
oral prodrug, dabigatran etexilate, in a rabbit model of venous
thrombosis. J Thromb Haemost 2007, 5(6):1237–1242.
57. Beier JP, Horch RE, Hess A, Arkudas A, Heinrich J, Loew J, Gulle H,
Polykandriotis E, Bleiziffer O, Kneser U: Axial vascularization of a large
volume calcium phosphate ceramic bone substitute in the sheep AV
loop model. J Tissue Eng Regen Med 2010, 4(3):216–223.
doi:10.1186/1746-6148-9-192
Cite this article as: Weigand et al.: New aspects on efficient
anticoagulation and antiplatelet strategies in sheep. BMC Veterinary
Research 2013 9:192.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
